The purpose of this study is to evaluate the safety and effectiveness of an investigational medication in slowing disease progression in adults diagnosed with mild to moderate Alzheimer’s disease. Qualified study participants and their study partner / caregiver will be asked to attend up to 48 office visits over 18 months. All study participants will be able to continue taking their current Alzheimer’s medications for the duration of the study. In addition to taking their current medications, participants will be randomly assigned to receive either: Dose A of the study medication, Dose B of the study medication, or Placebo. MRI images of the participants’ brains will be acquired periodically to measure changes in brain volume and assess the safety of the medication.
A Randomized, Double-Blind, Placebo-Controlled, Two Dose-Arm, Parallel Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% (IGN 10%) For the Treatment of Mild-to-Moderate Alzheimer’s Disease
This project was funded by: UCSD, Baxter, and GRECC
The term of this project was: July 2009 to June 2012
The number of subjects scanned during this project was: 10